Jan. 29, 2013
Corporation (NASDAQ: LIFE) today announced the establishment of the Global Influenza Network, a partnership including scientists at a number of the world's leading government public health organizations, veterinary agencies and research institutes in a collaborative effort to increase the speed and efficiency of influenza monitoring and vaccine development. Members of the network are sharing tools, experience and data using the Ion Personal Genome Machine (PGM™) semiconductor sequencing platform.
"Life Technologies exhibited leadership in infectious disease tracking when our scientists worked alongside federal officials to identify the cause of H1N1 outbreak in 2008," said
Gregory T. Lucier
, Chairman and Chief Executive Officer of Life Technologies. "We are very proud to now bring together a group of such distinguished organizations to tackle the continued threat of influenza worldwide."
Participating scientists include:
, head of the NGS Platform, and Mia Brytting, Ph.D., head of the microbial typing unit at the Swedish Institute for Communicable Disease Control (SMI);
, Ph.D., researcher at the Istituto Superiore di Sanita in
Mary Lea Killian
, microbiologist at the U.S. National Veterinary Service Laboratories in
at the J. Craig Venter Institute in
Partnership Develops Faster, More Reliable Flu Subtyping Methods
Annual seasonal influenza epidemics cause approximately 3 to 5 million cases of severe illness and 250,000 to 500,000 deaths, according to the World Health Organization (WHO). Pandemics caused by novel influenza strains can result in staggering death tolls; the "Spanish flu" of 1918 is believed to have killed 40 million people, or 3 percent of the global population, according to the WHO.